Puma Biotechnology | PBYI - Crediti Commerciali





Crediti Commerciali Cambiamento Data
Agios Pharmaceuticals USD 16.13M 5.56M 2026-03
Alnylam Pharmaceuticals USD 883.96M 106.39M 2026-03
Amgen USD 9.14B 432M 2026-03
Biogen USD 1.79B 76.6M 2026-03
BioMarin Pharmaceutical USD 903.91M 4.3M 2026-03
Daiichi Sankyo JPY 695.95B 79.1B 2025-12
Exelixis USD 328.95M 42.03M 2026-03
Gilead Sciences USD 4.74B 172M 2026-03
Glaxosmithkline GBP 10.49B 40.6M 2026-03
Incyte USD 1.05B 27.09M 2026-03
MacroGenics USD 10.42M 2.95M 2026-03
Moderna USD 71M 113M 2026-03
Novartis USD 9.6B 2.69B 2026-03
Pfizer USD 16.17B 332M 2026-03
PTC Therapeutics USD 181.62M 21.45M 2025-12
Puma Biotechnology USD 28.1M 3.52M 2024-06
Regeneron Pharmaceuticals USD 5.73B 10.1M 2026-03
Roche Holding CHF 13.34B 1.44B 2026-06
Sangamo BioSciences USD 581K 110K 2024-06
Sarepta Therapeutics USD 547.91M 149.68M 2026-03
Takeda JPY 876.35B 118.43B 2026-03
TG Therapeutics USD 392.05M 86.42M 2026-03
Ultragenyx Pharmaceutical USD 60M 98M 2026-03
Vanda Pharmaceuticals USD 47.1M 4.35M 2024-12
Vertex Pharmaceuticals USD 2B 56.7M 2026-03